Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Alphavirus envelope glycoproteins, primarily E1 and E2, are structural proteins that form icosahedral spikes on the surface of the virion. E2 is a type I transmembrane protein responsible for receptor binding and attachment to the host cell surface, while E1 is a class II fusion protein that mediates the fusion of the viral envelope with the host endosomal membrane upon acidification. These proteins are synthesized as a polyprotein precursor (p62-6K-E1) that is proteolytically processed during transport to the cell surface. Because they are the most exposed components of the virus, they serve as the primary targets for the host immune response and are the focus of vaccine and monoclonal antibody development. Therapeutic strategies often aim to block the E2-mediated attachment or the E1-mediated conformational change required for membrane fusion, thereby preventing viral entry and subsequent replication.
Neutralization of viral particles by blocking receptor attachment (E2) or inhibiting pH-dependent membrane fusion (E1) within the endosome.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alphavirus envelope glycoprotein (E1/E2).